Abgenix to become sole owner of Xenomouse fully human antibody technology
. Contact: . Kurt Leutzinger. Vice President and Chief Financial Officer . Abgenix Inc.. (510) 608-6575. or. Marion E. Glick. Porter Novelli. 212/601-8273 . . ABGENIX TO BECOME SOLE OWNER OF XENOMOUSE FULLY HUMAN ANTIBODY TECHNOLOGY. -Abgenix to Acquire Japan Tobacco's Interests in Xenotech Joint Venture -. . FREMONT, CALIFORNIA - December 20, 1999 - Abgenix, Inc. (Nasdaq: ABGX) will become t.... Contact: . Kurt Leutzinger . Abgenix, Inc.. Vice President and . Chief Financial Officer. (510) 608-6575. . Marion E. Glick. Porter Novelli. (212) 601-8273 . . Mark R. Vincent. CuraGen Corporation. Director, Corporate Communications. 1-888-GENOMICS. www.curagen.com. . . ABGENIX AND CURAGEN ESTABLISH LARGE-SCALE DRUG DEVELOPMENT ALLIANCE. Companies to Develop Genomics-based Human Antibody Drug...Abgenix initiates phase III clinical trial of graft versus host disease therapy
. . . . . Abgenix to Seek a Corporate Partner to Commercialize ABX-CBL . . FREMONT, Calif., December 7, 1999 - Abgenix, Inc. (Nasdaq: ABGX) is initiating a Phase III. clinical trial comparing its antibody, ABX-CBL, with standard therapy for patients with. steroid-resistant graft-versus-host disease (srGVHD), a serious, life-threatening disorder. Abgenix. also indicated that it would seek a...Abgenix reports positive clinical data with ABX-IL8 in Psoriasis
. . . FREMONT, Calif., November 30, 1999 - Abgenix, Inc. (Nasdaq: ABGX) today reported top level results. of its Phase I/II clinical trial with ABX-IL8, a fully human antibody developed with the company's. XenoMouse™ technology. Additional details will be presented at the Psoriasis: from Gene to Clinic. meeting in London on December 2,1999. The multi-center, placebo controlled trial inv.... Contact: . Kurt Leutzinger. Vice President and. Chief Financial Officer . Abgenix Inc.. (510) 608-6575. and. Marion E. Glick. Porter Novelli. 212/601-8273 . . Arthur Mandell. Senior Vice President, Corporate and Business Development. Human Genome Sciences. 301/309-8504. and . Kate de Santis. Director, Corporate Communications and Investor Relations. Human Genome Sciences . 301/251-6003 . . H.... FREMONT, CALIF., December 1, 1999 - Abgenix, Inc. (Nasdaq: ABGX) today announced that it has.signed a research license and option agreement with Chiron, Inc. ("Chiron") (Nasdaq: CHIR) under which.Chiron will use Abgenix's XenoMouse™ technology to generate fully human monoclonal antibodies to.an undisclosed antigen in the field of autoimmune diseases. In return, Abgenix will receive a.tech...Abgenix Reports Encouraging Preclinical Results With ABX-EGF In Cancer Research
. . .FREMONT, Calif., March 15, 1999 -- Abgenix, Inc. (Nasdaq: ABGX) reported today.in Cancer Research (Volume 59, Issue no. 6), encouraging results of preclinical.studies with its proprietary fully human monoclonal antibody, ABX-EGF. Developed.using the company's XenoMouseTM technology, ABX-EGF targets the receptor for.human epidermal growth factor (EGFr) which is overexpressed on many major h...